by | Jun 16, 2021
Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces that the recruitment of patients for the exploratory phase IIa study with KAND567 has ended after just over 80 percent of the originally planned number of COVID-19 patients have received their dose....
by | May 24, 2021
Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces today that the application for permission to start a phase IIa study evaluating the safety and cardioprotective effect of KAND567 in heart attack patients has been submitted to the UK Medicines and...
by | May 21, 2021
First quarter in briefNet sales for the period (January to March) amounted to SEK 0 million (SEK 0 million).R&D costs for the period amounted to SEK 8,2 million (SEK 9,7 million).Operating profit for the period amounted to SEK -9,0 million (SEK -11,1...
by | Jan 15, 2021
This is a translation of a press release in Swedish published December 29, 2020 Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces today that the company's new capsule product with KAND567 has been evaluated in a successful phase I study in...
by | Jan 15, 2021
This is a translation of a press release in Swedish published December 21, 2020 Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces that the company has established a Scientific Advisory Board consisting of three leading scientists in the fields of...
Recent Comments